Artificial intelligence-based biomarkers for treatment decisions in oncology
2025 · Trends in cancer · 35 citations
https://doi.org/10.1016/j.trecan.2024.12.001
M
Mihaela Aldea
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
361
Papers
2.5K
Citations
24
h-index
45
i10-index
Mihaela Aldea is an academic researcher from Harvard University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Colorectal Cancer Treatments and Studies & Cancer Genomics and Diagnostics. The author has an h-index of 24, co-authored 307 publications.
ORCID: 0000-0001-7685-051XPapers by this author
worksArsenic trioxide plus cisplatin/interferon α- 2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma
2011 · Hematology/Oncology and Stem Cell Therapy · 25 citations
https://doi.org/10.5144/1658-3876.2011.60
Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications
2023 · The Journal of Liquid Biopsy · 21 citations
https://doi.org/10.1016/j.jlb.2023.100007
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
2023 · Molecular Cancer · 15 citations
https://doi.org/10.1186/s12943-023-01878-9
Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates
2024 · Clinical Cancer Research · 12 citations
https://doi.org/10.1158/1078-0432.ccr-24-1993
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial
2023 · British Journal of Cancer · 9 citations
https://doi.org/10.1038/s41416-023-02514-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat